Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Gears To Make Otsuka’s MDR TB Drug In India

Executive Summary

Manufacturing plans for multidrug-resistant tuberculosis (MDR-TB) drug Deltyba (delamanid) in India appear to be gathering steam, with partners Otsuka and Mylan commencing the technology transfer process for the product, although activists are concerned about the broader contours of the arrangement. Deltyba is also expected to be used in children and adolescents in India.


Related Content

Call For India Compulsory Licenses For Last Resort TB Drugs
Otsuka Ties Up With Mylan To Advance MDR-TB Drug In India?
Latest WHO Essential Medicines List: New Drugs And A New Way Of Tackling Antibiotic Resistance


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts